Prognostic Biomarker in rectal cancer patients: Thymidylate Synthase for risk stratification after 5-FU-based neoadjuvant radiochemotherapy

Lena-Christin Conradi, Annalen Bleckmann, Markus Schirmer, Thilo Sprenger, Peter Jo, Kia Homayounfar, Hendrik A. Wolff, Hilka Rothe, Heinz Becker, Michael Ghadimi, Tim Beissbarth & Torsten Liersch
Introduction: Fluorouracil (5-FU) remains the backbone of neoadjuvant radiochemotherapy (RCT) as well as adjuvant therapeutic strategies in multimodal treatment of rectal cancer patients. Due to its central role as the major target of 5-FU thymidylate synthase (TS) is a promising biomarker in rectal[for full text, please go to the a.m. URL]